Aktis Oncology

CEO Matthew Roden, PhD, previously led corporate strategy and BD at Bristol Myers Squibb and brings capital markets experience from J.P. Morgan and UBS. CFO Kyle Kuvalanka has taken multiple companies public and led finance and BD at Blueprint and Syros. The CMO joined from Pfizer and the CSO has deep radiopharma experience.

Board and advisors include seasoned radiopharma leaders. Strategic validation from Lilly as an investor and collaborator further supports management quality.